LEGN - NASDAQ
Legend Biotech Corporation
$35.98
+3.1%Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
At a Glance
Live SnapshotLegend Biotech Corporation Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Weak cash conversion. Significant portion of earnings not converting to cash—review working capital trends and capital intensity.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Declining FCF warrants attention. Investigate whether due to temporary factors or fundamental deterioration.
Working Capital Impact
Significant working capital drain. Growth may be consuming cash through inventory buildup or receivables extension—monitor closely.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Legend Biotech Corporation Cash Flow Statement
LEGN • NASDAQ
| Legend Biotech Corporation Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||||
-297.6M | -158.1M | -520.1M | -445.7M | -407.2M | -308.3M | -130.4M | -1.6M | 9.4M | |
29M | 23.4M | 20.5M | 18.4M | 13.9M | 9.9M | 5.3M | 1.7M | 217K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -7.4M | -5.7M | 0.0 | |
0.0 | 68.9M | 47.7M | 34.3M | 20.2M | 4.8M | 1.3M | 704K | 0.0 | |
261.5M | -98.2M | 130.1M | 10.7M | 12.8M | 93.8M | -4.4M | -6.1M | 228.9M | |
-93.3M | 20M | -71.3M | 181M | 161.8M | -23.2M | 52.5M | 318.7M | -16.5M | |
-100.5M | -144M | -393.3M | -201.3M | -198.5M | -223M | -83.1M | 307.7M | -2.4M | |
INVESTING ACTIVITIES | |||||||||
-67.6M | -14.1M | -20.1M | -20.9M | -42.2M | -26.3M | -39.2M | -21M | -887K | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -460K | (20K) | (60K) | |
-4.6B | -2.7B | -4.9B | -655M | -378M | -72.7M | -390.4M | -6M | (0.0) | |
5.3B | 1.9B | 5.1B | 614.9M | 230.1M | 98.3M | 320.9M | 0.0 | 0.0 | |
0.0 | -54.3M | -100.5M | -16.1M | -4.9M | -23.5M | 50.5M | -75.2M | 55K | |
(711.5M) | -850.5M | (92.8M) | -77.1M | -195M | -24.2M | -58.7M | -102.3M | -827K | |
FINANCING ACTIVITIES | |||||||||
3.3M | 0.0 | 0.0 | 377.6M | 623.4M | 462.1M | 0.0 | 0.0 | 0.0 | |
0.0 | -4M | -3.8M | -2.6M | -1.4M | -2.6M | -5.1M | -219K | -32K | |
-3.6M | 9.7M | 795.2M | 2.9M | 4.6M | -1.1M | 19.7M | 2.7M | 3.4M | |
-300.8K | 5.7M | 791.5M | 378M | 626.7M | 618.9M | 14.7M | 2.5M | 3.3M | |
CASH FLOW SUMMARY | |||||||||
4.4M | -2.1M | 682K | -2.5M | 34K | 620K | 249K | 124K | 9K | |
615.1M | -991M | 491.7M | 97.1M | 233.2M | 372.3M | -126.8M | 208.1M | 128K | |
286.8M | 1.3B | 786M | 688.9M | 455.7M | 83.4M | 210.2M | 2.1M | 2M | |
901.9M | 286.7M | 1.3B | 786M | 688.9M | 455.7M | 83.4M | 210.2M | 2.1M | |
-168M | -158.1M | -416M | -223.6M | -243.9M | -253.3M | -122.2M | 286.7M | -3.3M |
SEC Filings
LEGN - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
6-K 6-K 2026 Q2 Q2 | June 02, 2026 | June 02, 2026 | 2026 | |
6-K 6-K 2026 Q2 Q2 | June 01, 2026 | June 01, 2026 | 2026 | |
6-K 6-K 2026 Q2 Q2 | May 21, 2026 | May 21, 2026 | 2026 | |
6-K 6-K 2026 Q1 Q1 | May 12, 2026 | March 31, 2026 | 2026 | |
6-K 6-K 2026 Q2 Q2 | April 14, 2026 | April 14, 2026 | 2026 | |
20-F 20-F 2025 FY FY | March 10, 2026 | December 31, 2025 | 2025 | |
6-K 6-K 2026 Q1 Q1 | March 10, 2026 | March 10, 2026 | 2026 | |
6-K 6-K 2026 Q1 Q1 | February 06, 2026 | February 06, 2026 | 2026 | |
6-K 6-K 2026 Q1 Q1 | January 23, 2026 | January 23, 2026 | 2026 | |
6-K 6-K 2026 Q1 Q1 | January 21, 2026 | January 21, 2026 | 2026 |
Related Guides
Continue your LEGN research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.